Diagnoplex SA and Unilabs Sign a Collaboration Agreement to Market the Colox® Non-Invasive Colon Cancer Screening Test
LAUSANNE, Switzerland, September 18, 2013 /PRNewswire/ –
Diagnoplex SA, a developer of molecular diagnostics for colorectal cancer and Unilabs,
a leading supplier of clinical laboratory and medical diagnostic imaging services in
Europe, signed a collaboration agreement to commercialize Colox(R), a minimally invasive
colorectal cancer assay within the Unilabs network. The test will be available initially
in the Swiss and Swedish markets.
The agreement combines Diagnoplex’s capacity to develop “high-return” molecular assays
with Unilabs’ leading position in the European diagnostics market. The agreement builds on
a solid collaborative effort between the two companies and enables Unilabs to further
differentiate itself through innovative molecular testing.
“This agreement opens a new and exciting chapter for Diagnoplex,” said Stavros
Therianos, founder and CEO of Diagnoplex SA. “We are able to enter into a strong
collaboration with a European market leader such as Unilabs thanks to a patient-focused
strategy for clinical product development. This collaboration demonstrates that a
step-by-step approach, for the development of molecular screening tests, can effectively
lead to the commercial availability of medically relevant diagnostics.”
Fernando de Gorgolas, Unilabs Group Marketing & Business Development Director, said,
“This collaboration with Diagnoplex is consistent with our strategy of launching
innovative tests that can bring a real benefit to patients and the healthcare community.
Colox will strengthen the role of our molecular genetics laboratories in the diagnosis and
monitoring of colorectal cancer.”
Thierry Mauvernay, Delegate of the Board of Debiopharm Group – a lead investor in
Diagnoplex – agreed, adding, “We are delighted that Diagnoplex has been able to establish
this collaboration with an important actor in diagnostic market. We believe the Colox
blood test has the potential to greatly increase the percentage of people that will be
correctly screened for colorectal cancer.”
Other investors of Diagnoplex SA include NeoMed, Novartis Bioventures and Initiative
Capital Romandie. Bourgeois Avocats in Lausanne, Switzerland, were involved with legal
aspects of the collaboration agreement.
Diagnoplex’s lead product, Colox(R), is a convenient and minimally invasive blood test
developed for the systematic screening of colorectal cancer. The gene signature underlying
Colox(R) has been designed to detect early and advanced disease stages with outstanding
results and reliability.
Colox(R) leverages the information from nucleic acids carried by peripheral blood
mononuclear cells (PBMCs). PBMCs are instrumental for tumor-host interactions, the
so-called “host response”, and are involved at the earliest stages of tumor formation. Our
ability to screen for the host response enables us to detect colorectal cancer risk at the
earliest and even pre-cancerous stages.
For more information about Diagnoplex, please visit: http://www.diagnoplex.com
Unilabs is a leading diagnostic services company. We operate more than 120
laboratories and 44 radiology units in Denmark, Finland, France, Italy, Norway, Portugal,
Russia, Spain, Sweden, Switzerland, and the United Kingdom. Our customers are public and
private healthcare providers, county councils, the general public, insurance companies,
the pharmaceutical industry and CROs. We supply medical laboratory services within:
laboratory medicine, genetic testing, medical imaging, cellular pathology, reproductive
medicine, drug development services and clinical trials. For more information please visit
Diagnoplex S.A. Contact Stavros Therianos, Ph.D. Chief Executive Officer Tel. +41-21-989-20-00 email@example.com Unilabs Contact Fernando de Gorgolas Group Marketing & Business Development Director Tel. +41-22-909-77-77 Fernando.DeGorgolas@unilabs.com Additional media contacts : London Maitland Brian Hudspith Tel.: +44(0)20-7379-5151 firstname.lastname@example.org New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive Tel.: +1-212-845-4292 Fax: +1-212-845-4260 email@example.com
SOURCE Diagnoplex SA and Unilabs